Pharmaceutical company stocks were among the winners in early trading Wednesday as Republicans’ sweeping election victory eased concerns that Democrats would enact controls on drug prices. Eli Lilly and Co. shares jumped 4 percent.
The company's top-selling product, the insulin Humalog, saw U.S. sales by volume rise 10 percent in the third quarter. But because of rebates and other discounts, revenue dropped 14 percent.
Makers of insulin became the latest target for Sen. Bernie Sanders, who has been going after pharmaceutical companies one by one over the issue of high U.S. drug prices.
Drugmakers including Eli Lilly and Co. are becoming increasingly vocal in fighting a California ballot proposition designed to bring down prices on prescription medicine.
Sales of Lilly's Humalog insulin, its top-selling product, fell 9 percent, to $641 million, offsetting gains by a stable of new drugs that is helping the company weather a blitz of patent expirations.
Lartruvo is the first front-line therapy approved by the FDA to treat soft tissue sarcomas since doxorubicin more than 40 years ago.
Eli Lilly and Co. is pledging $90 million over five years to improve access to treatment for diabetes, cancer and tuberculosis in developing countries—the latest push in its philanthropic strategy of building health care systems around the world and increasing the market for its prescription drugs.
The residents who sued sought to revoke the school’s property-tax exemption, in part because Princeton shares commercial royalties with faculty from a patent that Indianapolis-based Eli Lilly and Co. turned into the cancer drug Alimta.
For more than two years, Eli Lilly and Co. has pushed the message that the worst days are over and a brighter future is just around the corner. Now, finally, Wall Street is starting to believe.
Pharma giant Novo Nordisk announced Thursday that it is cutting 1,000 jobs after slashing forecasts for 2016, citing lower prices for diabetes drugs. Novo and competitors such as Indianapolis-based Eli Lilly will likely have to keep tightening their belts as prices and profit margins fall, experts say.
On Jan. 1, Dave Ricks becomes CEO of drugmaker Eli Lilly and Co. as it tries to launch new products after a tough stretch of patent expirations. To prepare, Ricks has spent a lot of time with outgoing CEO John Lechleiter “learning from the master.”
Drugmakers facing a price war in the diabetes market, including Indianapolis-based Eli Lilly and Co., are betting on new technologies to withstand the competition.
Eli Lilly and Co. and its partner cannot stop competitors from selling generic versions of testosterone treatment Axiron, a federal judge in Indianapolis has ruled.
Named AZD3293, the drug belongs to a novel class of drugs that block production of amyloid, a protein that causes plaque to build up in the brain of Alzheimer’s patients.
Seven men who took Cialis pills to treat erectile dysfunction sued Indianapolis drugmaker Eli Lilly and Co. this week, claiming they later suffered from skin cancer that was related to the medicine.
Dave Ricks will begin guiding the company during a period of relative calm compared with the trying times John Lechleiter navigated during his eight years at the helm.
Over the last eight years, Eli Lilly relied on a three-decade company veteran to steer it through declining sales and a struggling product pipeline. Now, it’ll rely on another long-time executive for its next chapter.
John Lechleiter has been the company’s CEO since 2008. The announcement Wednesday morning of his retirement comes one day after the firm announced strong revenue and profit for its second quarter, indicating that Lechleiter’s initiatives have paid off.
CEO John Lechleiter said the company's strong R&D pipeline has put it on track to report average annual revenue growth of at least 5 percent through the remainder of the decade.
A hot-selling drug for diabetes sold by Eli Lilly and Co. and a co-partner just got another potential boost, as a government panel narrowly recommended that the companies should be allowed to claim that the drug cuts the risk of cardiovascular death.
